Literature DB >> 26531818

Creatinine-based equations for the adjustment of drug dosage in an obese population.

Antoine Bouquegneau1, Emmanuelle Vidal-Petiot2, Olivier Moranne3, Christophe Mariat4, Jean-Jacques Boffa5, François Vrtovsnik6, André-Jean Scheen7, Jean-Marie Krzesinski1, Martin Flamant2, Pierre Delanaye1.   

Abstract

AIM: For drug dosing adaptation, the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines recommend using estimated glomerular filtration rate (eGFR) by the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation, after 'de-indexation' by body surface area (BSA). In pharmacology, the Cockcroft-Gault (CG) equation is still recommended to adapt drug dosage. In the context of obesity, adjusted ideal body weight (AIBW) is sometimes preferred to actual body weight (ABW) for the CG equation. The aim of the present study was to compare the performance of the different GFR-estimating equations, non-indexed or de-indexed by BSA for the purpose of drug-dosage adaptation in obese patients.
METHODS: We analysed data from patients with a body mass index (BMI) higher than 30 kg m(-2) who underwent a GFR measurement. eGFR was calculated using the CKD-EPI and Modification of Diet in Renal Disease (MDRD) equations, de-indexed by BSA, and the CG equation, using either ABW, AIBW or lean body weight (LBW) for the weight variable and compared with measured GFR, expressed in ml min(-1).
RESULTS: In our population of obese patients, use of the AIBW instead of the ABW in the CG equation, markedly improved the overall accuracy of this equation [57% for CGABW and 79% for CGAIBW (P < 0.05)]. For high BMI (over 40 kg m(-2)), the accuracy of the CG equations is no different when using LBW than when using AIBW. The MDRD and CKD-EPI equations de-indexed by the BSA also performed well, with an overall higher accuracy for the MDRD de-indexed equation [(80% and 76%, respectively (P < 0.05)].
CONCLUSIONS: The de-indexed MDRD equation appeared to be the most suitable for estimating the non-indexed GFR for the purpose of drug dosage adaptation in obese patients.
© 2015 The British Pharmacological Society.

Entities:  

Keywords:  creatinine-based equations; drug dosage; glomerular filtration rate; obesity

Mesh:

Substances:

Year:  2016        PMID: 26531818      PMCID: PMC4833161          DOI: 10.1111/bcp.12817

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  69 in total

1.  Reference range and method comparison studies for enzymatic and Jaffé creatinine assays in plasma and serum and early morning urine.

Authors:  B C Mazzachi; M J Peake; V Ehrhardt
Journal:  Clin Lab       Date:  2000       Impact factor: 1.138

2.  The origin of the "ideal" body weight equations.

Authors:  M P Pai; F P Paloucek
Journal:  Ann Pharmacother       Date:  2000-09       Impact factor: 3.154

3.  When to conduct a renal impairment study during drug development: US Food and Drug Administration perspective.

Authors:  S-M Huang; R Temple; S Xiao; L Zhang; L J Lesko
Journal:  Clin Pharmacol Ther       Date:  2009-11       Impact factor: 6.875

4.  A unified pharmacokinetic approach to individualized drug dosing.

Authors:  Evan J Begg; Paul K L Chin
Journal:  Br J Clin Pharmacol       Date:  2012-03       Impact factor: 4.335

Review 5.  Cardiovascular effects of current and future anti-obesity drugs.

Authors:  Simon Comerma-Steffensen; Martin Grann; Charlotte U Andersen; Jorgen Rungby; Ulf Simonsen
Journal:  Curr Vasc Pharmacol       Date:  2014-05       Impact factor: 2.719

6.  Association between body mass index and CKD in apparently healthy men.

Authors:  Rebecca P Gelber; Tobias Kurth; Annamaria T Kausz; Joann E Manson; Julie E Buring; Andrew S Levey; J Michael Gaziano
Journal:  Am J Kidney Dis       Date:  2005-11       Impact factor: 8.860

7.  Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate.

Authors:  Andrew S Levey; Josef Coresh; Tom Greene; Lesley A Stevens; Yaping Lucy Zhang; Stephen Hendriksen; John W Kusek; Frederick Van Lente
Journal:  Ann Intern Med       Date:  2006-08-15       Impact factor: 25.391

8.  Dosing of cytotoxic chemotherapy: impact of renal function estimates on dose.

Authors:  M J Dooley; S G Poole; D Rischin
Journal:  Ann Oncol       Date:  2013-08-07       Impact factor: 32.976

9.  Comparison of equations for dosing of medications requiring renal adjustment.

Authors:  Bethany A Lessard; Kathy Zaiken
Journal:  J Am Pharm Assoc (2003)       Date:  2013 Jan-Feb

Review 10.  Dosing of medications in morbidly obese patients in the intensive care unit setting.

Authors:  Brian L Erstad
Journal:  Intensive Care Med       Date:  2003-11-19       Impact factor: 17.440

View more
  16 in total

1.  Discrepancies between the Cockcroft-Gault and Chronic Kidney Disease Epidemiology (CKD-EPI) Equations: Implications for Refining Drug Dosage Adjustment Strategies.

Authors:  Pierre Delanaye; Fabrice Guerber; André Scheen; Timothy Ellam; Antoine Bouquegneau; Dorra Guergour; Christophe Mariat; Hans Pottel
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447

2.  The estimation of GFR and the adjustment for BSA in overweight and obesity: a dreadful combination of two errors.

Authors:  Marina López-Martínez; Sergio Luis-Lima; Enrique Morales; Maruja Navarro-Díaz; Natalia Negrín-Mena; Tomás Folgueras; Beatriz Escamilla; Sara Estupiñán; Patricia Delgado-Mallén; Domingo Marrero-Miranda; Ana González-Rinne; Rosa María Miquel-Rodríguez; Maria Angeles Cobo-Caso; Laura Díaz-Martín; Alejandro Jiménez-Sosa; Federico González-Rinne; Armando Torres; Esteban Porrini
Journal:  Int J Obes (Lond)       Date:  2019-10-22       Impact factor: 5.095

3.  Influence of the recipient body mass index on the outcomes after kidney transplantation.

Authors:  Juliane Liese; Nils Bottner; Stefan Büttner; Alexander Reinisch; Guido Woeste; Markus Wortmann; Ingeborg A Hauser; Wolf Otto Bechstein; Frank Ulrich
Journal:  Langenbecks Arch Surg       Date:  2017-05-10       Impact factor: 3.445

Review 4.  Kidney Function in Obesity-Challenges in Indexing and Estimation.

Authors:  Alex R Chang; Waleed Zafar; Morgan E Grams
Journal:  Adv Chronic Kidney Dis       Date:  2018-01       Impact factor: 3.620

Review 5.  Methods of Estimating Kidney Function for Drug Dosing in Special Populations.

Authors:  Laura A Hart; Gail D Anderson
Journal:  Clin Pharmacokinet       Date:  2018-08       Impact factor: 6.447

Review 6.  The global burden of chronic kidney disease: estimates, variability and pitfalls.

Authors:  Richard J Glassock; David G Warnock; Pierre Delanaye
Journal:  Nat Rev Nephrol       Date:  2016-12-12       Impact factor: 28.314

7.  Creatinine-based equations for the adjustment of drug dosage in an obese population.

Authors:  Antoine Bouquegneau; Emmanuelle Vidal-Petiot; Olivier Moranne; Christophe Mariat; Jean-Jacques Boffa; François Vrtovsnik; André-Jean Scheen; Jean-Marie Krzesinski; Martin Flamant; Pierre Delanaye
Journal:  Br J Clin Pharmacol       Date:  2016-01-17       Impact factor: 4.335

8.  Accuracy of freely available online GFR calculators using the CKD-EPI equation.

Authors:  Sarah Seiberth; Theresa Terstegen; Dorothea Strobach; David Czock
Journal:  Eur J Clin Pharmacol       Date:  2020-06-19       Impact factor: 2.953

9.  Tobramycin Clearance Is Best Described by Renal Function Estimates in Obese and Non-obese Individuals: Results of a Prospective Rich Sampling Pharmacokinetic Study.

Authors:  Cornelis Smit; Roeland E Wasmann; Marinus J Wiezer; Hendricus P A van Dongen; Johan W Mouton; Roger J M Brüggemann; Catherijne A J Knibbe
Journal:  Pharm Res       Date:  2019-05-30       Impact factor: 4.200

10.  Iohexol plasma clearance for measuring glomerular filtration rate in clinical practice and research: a review. Part 2: Why to measure glomerular filtration rate with iohexol?

Authors:  Pierre Delanaye; Toralf Melsom; Natalie Ebert; Sten-Erik Bäck; Christophe Mariat; Etienne Cavalier; Jonas Björk; Anders Christensson; Ulf Nyman; Esteban Porrini; Giuseppe Remuzzi; Piero Ruggenenti; Elke Schaeffner; Inga Soveri; Gunnar Sterner; Bjørn Odvar Eriksen; Flavio Gaspari
Journal:  Clin Kidney J       Date:  2016-09-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.